This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Age-targeted dose allocation can halve COVID-19 vaccine requirements
Preprint
in English
| medRxiv
| ID: ppmedrxiv-20208108
ABSTRACT
In anticipation of COVID-19 vaccine deployment, we use an age-structured mathematical model to investigate the benefits of optimizing age-specific dose allocation to suppress the transmission, morbidity and mortality of SARS-CoV-2 and the associated disease, COVID-19. To minimize transmission, we find that the highest priority individuals across 179 countries are typically those between 30 and 59 years of age because of their high contact rates and higher risk of infection and disease. Conversely, morbidity and mortality are initially most effectively reduced by targeting 60+ year olds who are more likely to experience severe disease. However, when population-level coverage is sufficient -- such that herd immunity can be achieved through targeted dose allocation -- prioritizing middle-aged individuals becomes the most effective strategy to minimize hospitalizations and deaths. For each metric considered, we show that optimizing the allocation of vaccine doses can more than double their effectiveness.
cc_no
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Type of study:
Prognostic study
Language:
English
Year:
2020
Document type:
Preprint